<h1 style="color: #ff681d;">To mark the arrival of <strong>ORKAMBI™</strong> (lumacaftor/ivacaftor) in the UK</h1>
<br/>
<p style="margin-right: 15px;">The European Commission has announced the approval of ORKAMBI™ (lumacaftor/ivacaftor) for the treatment of cystic fibrosis in patients aged 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.</p>
<p style="margin-right: 15px;">Please join Professor Stuart Elborn, Queen’s University Belfast, in a 30 minutes webcast to discuss the approval of ORKAMBI™, its indication, supporting clinical data and SmPC, as well as answering questions you may have about the data. You are also invited to submit questions during the webcast via this website, which will be followed up by a key account manager or medical scientific liaison.</p>